Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ChemGenex Pharmaceuticals Ltd.

Division of Teva Pharmaceutical Industries Ltd.
www.chemgenex.com

Latest From Itero Biopharmaceuticals Inc.

Fertility Market Poised For Growth Spurt After Fallow Decade

Late-stage pipeline is dominated by follicle stimulating hormones, split between “biobetters” and biosimilars. Next-generation oxytocin antagonists are leading candidates for the next novel entities in infertility.

BioPharmaceutical

Watson Continues Expansion Of Women’s Health Biz With Uteron Buy

Watson has added a slew of products to its portfolio over the last three years to become a leader in the women’s health space. Its acquisition of Uteron gives it at least three more products for that portfolio.

BioPharmaceutical Deals

Watson Becomes Actavis: Name Change To Reflect Greater International Focus

Watson’s merger with Actavis will create the world’s third-largest generic drug company, to be known as Actavis, with significant ex-U.S. market share, especially in the U.K., Nordic countries and Russia.

BioPharmaceutical North America

Chief Executive Change At Teva Illustrates Diversification Emphasis At Major Generic Drug Makers

Most of the top 20 generic drug makers are subsidiaries of diversified pharmas or smaller generics-only plays based in the Far East. But diversification, although long a goal, is now urgent for the three major independent generic firms – Teva, Mylan and Watson.

BioPharmaceutical Europe
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Alias(es)
  • AGT Biosciences Ltd.
  • ChemGenex Therapeutics Inc.
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Australia
  • Parent & Subsidiaries
  • Teva Pharmaceutical Industries Ltd.
  • Senior Management
  • Greg Collier, PhD, CEO
    James Campbell, PhD, CFO & Co. Sec'y, COO
    Adam R Craig, MD, PhD, SVP, CMO
  • Contact Info
  • ChemGenex Pharmaceuticals Ltd.
    Phone: (61) 3 5223 9900
    Level 4, 199 Moorabool St.
    Geelong, 3220
    Australia
Advertisement
Advertisement
UsernamePublicRestriction

Register